Fady Ibraham Malik Sells 3,500 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 3,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $77.37, for a total transaction of $270,795.00. Following the completion of the transaction, the executive vice president owned 153,902 shares of the company’s stock, valued at approximately $11,907,397.74. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, April 21st, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.69, for a total transaction of $229,915.00.
• On Tuesday, April 7th, Fady Ibraham Malik sold 4,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.11, for a total transaction of $292,995.00.
• On Tuesday, March 17th, Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock. The stock was sold at an average price of $62.15, for a total transaction of $747,850.95.
• On Monday, March 9th, Fady Ibraham Malik sold 2,907 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total transaction of $176,513.04.

Cytokinetics Stock Down 2.9%

NASDAQ:CYTK opened at $74.84 on Thursday. The business’s 50-day simple moving average is $64.13 and its two-hundred day simple moving average is $63.75. The stock has a market cap of $9.30 billion, a PE ratio of -10.94 and a beta of 0.38. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $80.20.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.67). The business had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. During the same period last year, the company earned ($1.36) EPS. The business’s revenue was up 1112.5% on a year-over-year basis. Sell-side analysts anticipate that Cytokinetics, Incorporated will post -6.31 earnings per share for the current fiscal year.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline pivotal Phase‑3 success — the ACACIA‑HCM trial of aficamten (non‑obstructive HCM) met both dual primary endpoints with supportive secondary data, materially de‑risking the program and boosting commercial/regulatory prospects. Read More.
• Positive Sentiment: Early commercial traction and revenue beat — MYQORZO U.S. launch showed ~275 HCPs prescribing to ~680 patients in Q1 and generated ~$4.8M in partial‑quarter net product revenue; company reported Q1 revenue of $19.36M (well above consensus) and ~$1.1B cash on hand to fund launch. Read More.
• Positive Sentiment: Analyst momentum — several firms raised price targets and reiterated buy/outperform views following the trial & launch updates, supporting upside sentiment. Read More.
• Neutral Sentiment: Q1 EPS in line but losses continue — GAAP loss of ($1.67) matched estimates even as revenue surprised to the upside, highlighting strong top‑line launch execution but ongoing operating losses while scaling. Read More.
• Neutral Sentiment: Insider selling under 10b5‑1 plans — EVPs Andrew Callos and Fady Malik disclosed multi‑sale transactions executed via Rule 10b5‑1 plans; these are planned sales (not necessarily negative on fundamentals) but can prompt near‑term investor attention. Read More.
• Negative Sentiment: Planned $650M common stock offering — the proposed underwritten offering would fund commercialization and development but introduces near‑term dilution risk and is likely the main driver of selling pressure following the earlier rally. Read More.

Institutional Investors Weigh In On Cytokinetics

Large investors have recently bought and sold shares of the business. Woodline Partners LP lifted its position in Cytokinetics by 676.1% during the third quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after purchasing an additional 1,435,422 shares during the last quarter. Norges Bank bought a new stake in shares of Cytokinetics in the 4th quarter worth about $51,281,000. Deep Track Capital LP raised its position in shares of Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after buying an additional 650,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Cytokinetics by 151,987.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock valued at $35,949,000 after buying an additional 565,393 shares in the last quarter. Finally, Foresite Capital Management IV LLC bought a new position in shares of Cytokinetics in the 3rd quarter valued at about $25,188,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CYTK. Needham & Company LLC increased their price objective on shares of Cytokinetics from $85.00 to $102.00 and gave the company a “buy” rating in a report on Tuesday. Royal Bank Of Canada upped their target price on shares of Cytokinetics from $101.00 to $119.00 and gave the stock an “outperform” rating in a research report on Wednesday. Truist Financial set a $106.00 target price on shares of Cytokinetics in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a $90.00 price target on shares of Cytokinetics in a report on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.75.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.